Abstract: A solid state electrolyte having a garnet type crystal structure is provided. The chemical composition of the solid state electrolyte includes lithium, lanthanum, zirconium, oxygen, and sulfur. The content of sulfur in the solid state electrolyte is between 5 mol % and 35 mol % based on the content of oxygen in the solid state electrolyte. A solid state battery including a positive electrode layer, a negative electrode layer, and a solid state electrolyte layer is also provided. The solid state electrolyte layer is disposed between the positive electrode layer and the negative electrode layer. The solid state electrolyte layer includes the solid state electrolyte.

Abstract: The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein R1, R2, R3, and R4 are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts or co-crystals thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.

Abstract: A high-voltage positive electrode material for a lithium battery and a preparation method thereof are provided. The high-voltage positive electrode material for a lithium battery includes a material represented by the following formula (1): LiNi0.5-x-yMn1.5-x-yMg3xCr2yO4??(1) wherein x>0, y>0, and 0<3x+2y?0.1.

Abstract: A cathode of a lithium ion battery is provided. The cathode of a lithium ion battery includes a collector material. A first electrode layer including a lithium manganese iron phosphate (LMFP) material is disposed on a surface of the collector material. A second electrode layer including an active material is disposed on the first electrode layer. The active material includes lithium nickel manganese cobalt oxide (NMC), lithium nickel cobalt aluminum oxide (NCA), lithium cobalt oxide (LCO), Li-rich cathode material, or a combination thereof.

Abstract: A cathode of a lithium ion battery is provided. The cathode of a lithium ion battery includes a collector material. A first electrode layer including a lithium manganese iron phosphate (LMFP) material is disposed on a surface of the collector material. A second electrode layer including an active material is disposed on the first electrode layer. The active material includes lithium nickel manganese cobalt oxide (NMC), lithium nickel cobalt aluminum oxide (NCA), lithium cobalt oxide (LCO), Li-rich cathode material, or a combination thereof.

Abstract: The present invention discloses an overlay switch (OSW) and a method used by the same. A received unicast packet needs to pass a waypoint chain including a number of waypoints. A network address of a first waypoint of the waypoint chain and an underlay network address of a second OSW connected to the first waypoint are obtained. In response to a determination that the second OSW is not the first OSW the unicast packet is encapsulated into a first underlay network packet according to a specification of an overlay network. A field of a destination header of the first underlay network packet includes the underlay network address of the second OSW. A source port field of a user datagram protocol (UDP) header is set to indicate a waypoint index included in a corresponding waypoint chain. The first underlay network packet is sent to the second OSW.

Abstract: The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein R1, R2, R3, and R4 are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts or co-crystals thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.

Abstract: The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein R1, R2, R3, and R4 are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk. In certain embodiments, also disclosed are methods for treating a cancer in a subject (e.g., a human) in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, in combination with a vinca-alkaloid, or a pharmaceutically acceptable salt thereof.

Abstract: A conductive paper electrode includes a paper, a carbon powder layer, a graphite layer and a nanostructural layer. The carbon powder layer is positioned over the paper. The graphite layer is positioned over the carbon powder layer. The nanostructural layer is positioned over the graphite layer. An electrochemical capacitor includes two conductive paper electrodes and an electrolyte interposed therebetween.

Abstract: An electrolyte includes a lithium-containing quasi-ionic liquid and a gel. The lithium-containing quasi-ionic liquid includes an organic compound having at least one acylamino group, and a lithium salt. A flexible electrode includes the lithium-containing quasi-ionic liquid and the gel. The gel has a network structure, and the lithium-containing quasi-ionic liquid is sealed in the network structure. A flexible electronic device includes a flexible electronic component, and the flexible electrode is electrically connected to the flexible electronic component.

Abstract: A high-voltage positive electrode material for a lithium battery and a preparation method thereof are provided. The high-voltage positive electrode material for a lithium battery includes a material represented by the following formula (1): LiNi0.5-x-yMn1.5-x-yMg3xCr2yO4??(1) wherein x>0, y>0, and 0<3x+2y?0.1.

Abstract: The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein X1, X2, X3, R2, R3, R4, R5, and Y are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.

Abstract: The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein R1, R2, R3, and R4 are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts or co-crystals thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.

Abstract: The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein R1, R2, R3, and R4 are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk. In certain embodiments, also disclosed are methods for treating a cancer in a subject (e.g., a human) in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, in combination with a vinca-alkaloid, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention discloses an overlay switch (OSW) and a method used by the same. A received unicast packet needs to pass a waypoint chain including a number of waypoints. A network address of a first waypoint of the waypoint chain and an underlay network address of a second OSW connected to the first waypoint are obtained. In response to a determination that the second OSW is not the first OSW the unicast packet is encapsulated into a first underlay network packet according to a specification of an overlay network. A field of a destination header of the first underlay network packet includes the underlay network address of the second OSW. A source port field of a user datagram protocol (UDP) header is set to indicate a waypoint index included in a corresponding waypoint chain. The first underlay network packet is sent to the second OSW.

Abstract: A sulfur doped oxide solid electrolyte powder is provided. The amount of sulfur is 1 wt % to 5 wt % based on the weight of the sulfur doped oxide solid electrolyte powder. A solid state battery is also provided. The solid state battery includes a positive electrode layer, a negative electrode layer, and an electrolyte layer. The electrolyte layer includes the above sulfur doped oxide solid electrolyte powder.

Abstract: The present invention discloses an overlay switch (OSW) and a method used by the same. A received unicast packet needs to pass a waypoint chain including a number of waypoints. A network address of a first waypoint of the waypoint chain and an underlay network address of a second OSW connected to the first waypoint are obtained. In response to a determination that the second OSW is not the first OSW the unicast packet is encapsulated into a first underlay network packet according to a specification of an overlay network. A field of a destination header of the first underlay network packet includes the underlay network address of the second OSW. The first underlay network packet is sent to the second OSW.

Abstract: The invention relates to a refrigerant circuit for thermally conditioning a vehicle passenger compartment, comprising a plurality of branches containing at least one exchanger, of which branch a first branch is in series with a second branch and a third branch, said second branch being in parallel with said third branch, and a means of placing the third branch m communication with the second branch, said means being installed between a sector of the third branch which sector is situated downstream of an external exchanger and a portion of the second branch which is situated upstream of a first control member.

Abstract: A lithium positive electrode material is provided, which includes a host material and a doping material doped into the host material, wherein the doping material has a chemical formula of LiyLazZrwAluO12+(u*3/2), wherein 5?y?8, 2?z?5, 1?w?3, and 0<u<1. The lithium positive electrode material may collocate with carbon material and binder to form a positive electrode for a lithium battery.